Alpha(1A)- and Alpha(1B)-adrenergic Receptors Differentially Modulate Antidepressant-like Behavior in the Mouse
Authors
Affiliations
Tricyclic antidepressant (TCA) drugs are used for the treatment of chronic depression, obsessive-compulsive disorder (OCD), and anxiety-related disorders. Chronic use of TCA drugs increases the expression of alpha(1)-adrenergic receptors (alpha(1)-ARs). Yet, it is unclear whether increased alpha(1)-AR expression contributes to the antidepressant effects of these drugs or if this effect is unrelated to their therapeutic benefit. In this study, mice expressing constitutively active mutant alpha(1A)-ARs (CAM alpha(1A)-AR) or CAM alpha(1B)-ARs were used to examine the effects of alpha(1A)- and alpha(1B)-AR signaling on rodent behavioral models of depression, OCD, and anxiety. CAM alpha(1A)-AR mice, but not CAM alpha(1B)-AR mice, exhibited antidepressant-like behavior in the tail suspension test and forced swim test. This behavior was reversed by prazosin, a selective alpha(1)-AR inverse agonist, and mimicked by chronically treating wild type mice with cirazoline, an alpha(1A)-AR agonist. Marble burying behavior, commonly used to model OCD in rodents, was significantly decreased in CAM alpha(1A)-AR mice but not in CAM alpha(1B)-AR mice. In contrast, no significant differences in anxiety-related behavior were observed between wild type, CAM alpha(1A)-AR, and CAM alpha(1B)-AR animals in the elevated plus maze and light/dark box. This is the first study to demonstrate that alpha(1A)- and alpha(1B)-ARs differentially modulate antidepressant-like behavior in the mouse. These data suggest that alpha(1A)-ARs may be a useful therapeutic target for the treatment of depression.
Fung K, Baye F, Baik S, McDonald C PLoS One. 2024; 19(8):e0309222.
PMID: 39172922 PMC: 11340942. DOI: 10.1371/journal.pone.0309222.
Zhang M, Liu L, Xu Y, Wang W, Qiu N, Zhang F Metab Brain Dis. 2023; 38(7):2465-2476.
PMID: 37256468 DOI: 10.1007/s11011-023-01242-2.
Perez D Int J Mol Sci. 2023; 24(4).
PMID: 36835598 PMC: 9963459. DOI: 10.3390/ijms24044188.
Peric I, Ljesevic M, Beskoski V, Nikolic M, Filipovic D Psychopharmacology (Berl). 2022; 239(9):2955-2974.
PMID: 35776189 DOI: 10.1007/s00213-022-06180-y.
Silva S, Bicker J, Falcao A, Fortuna A Pharmaceutics. 2021; 13(11).
PMID: 34834391 PMC: 8624696. DOI: 10.3390/pharmaceutics13111975.